2170 related articles for article (PubMed ID: 28442273)
1. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
2. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
3. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
4. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
5. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.
Kettner NM; Voicu H; Finegold MJ; Coarfa C; Sreekumar A; Putluri N; Katchy CA; Lee C; Moore DD; Fu L
Cancer Cell; 2016 Dec; 30(6):909-924. PubMed ID: 27889186
[TBL] [Abstract][Full Text] [Related]
6. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.
Cheng Z; Chen Y; Schnabl B; Chu H; Yang L
J Adv Res; 2024 May; 59():173-187. PubMed ID: 37356804
[TBL] [Abstract][Full Text] [Related]
7. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
[TBL] [Abstract][Full Text] [Related]
8. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
9. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
[TBL] [Abstract][Full Text] [Related]
10. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
11. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
12. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease.
Chen Z; Yu R; Xiong Y; Du F; Zhu S
Lipids Health Dis; 2017 Oct; 16(1):203. PubMed ID: 29037210
[TBL] [Abstract][Full Text] [Related]
13. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
15. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
17. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
18. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
19. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
20. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
